Paradoxes of adherence and drug resistance to HIV antiretroviral therapy | Zendy

David R. Bangsberg | Zendy; Andrew R. Moss | Zendy; Steven G. Deeks | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Paradoxes of adherence and drug resistance to HIV antiretroviral therapy

Author(s) -

David R. Bangsberg,

Andrew R. Moss,

Steven G. Deeks

Publication year - 2004

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkh162

Subject(s) - drug resistance , protease inhibitor (pharmacology) , ritonavir , antiretroviral therapy , medicine , nucleoside reverse transcriptase inhibitor , reverse transcriptase inhibitor , hiv drug resistance , virology , protease , combination therapy , pharmacotherapy , immunology , human immunodeficiency virus (hiv) , pharmacology , viral load , biology , microbiology and biotechnology , biochemistry , enzyme

Public health debates about providing HIV antiretroviral therapy to impoverished populations have centred on the relationship between adherence and risk of drug resistance. Recent data indicate that each antiretroviral therapeutic class has a unique adherence-resistance relationship. Resistance to single protease inhibitor therapy occurs most frequently at moderate to high levels of adherence, resistance to non-nucleoside reverse transcriptase inhibitor therapy occurs at low to moderate levels of adherence, and resistance to ritonavir-boosted protease inhibitor therapy is most likely to occur at middle ranges of adherence. These dynamic relationships should be considered in balancing the individual and public health benefits of therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research